Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma.

[1]  J. Cadeddu,et al.  Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type , 2019, EBioMedicine.

[2]  R. Motzer,et al.  Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. , 2018, The Lancet. Oncology.

[3]  L. Egevad,et al.  Rhabdoid and Undifferentiated Phenotype in Renal Cell Carcinoma: Analysis of 32 Cases Indicating a Distinctive Common Pathway of Dedifferentiation Frequently Associated With SWI/SNF Complex Deficiency , 2017, The American journal of surgical pathology.

[4]  E. Plimack,et al.  Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. , 2016, The Lancet. Oncology.

[5]  J. Cheville,et al.  Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death , 2015, Modern Pathology.

[6]  J. Brugarolas,et al.  Cooperation and antagonism among cancer genes: the renal cancer paradigm. , 2013, Cancer research.

[7]  P. Kapur,et al.  Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. , 2013, The Lancet. Oncology.

[8]  N. Grishin,et al.  BAP1 loss defines a new class of renal cell carcinoma , 2012, Nature Genetics.

[9]  J. Choe,et al.  SWI/SNF Complex Interacts with Tumor Suppressor p53 and Is Necessary for the Activation of p53-mediated Transcription* , 2002, The Journal of Biological Chemistry.

[10]  Quyen N. Do,et al.  Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade. , 2017, Cancer discovery.